Glucocorticoid on the Prognosis of TEVAR

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the potential prognostic effect of glucocorticoid on the postoperative aorta-related adverse events after aortic dissections patients underwent thoracic endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will be intravenously given within 2h after TEVAR.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Treatments: Glucocorticoids; Methylprednisolone

Criteria

Inclusion Criteria:

1. age from 18 to 80, male or unpregnant female;

2. diagnosed as aortic dissection, excluding intramural hematoma and penetrating aortic ulcer;

3. complicated aortic dissection with definite indications of TEVAR;

4. voluntarily signed the informed consent form;

5. good compliance with the instructions and cooperate with follow-up.

Exclusion Criteria:

1. no appropriate vessel approaches;

2. patients with connective tissue diseases (such as Marfan syndrome);

3. patients with endocrine disease,such as diabetes mellitus, or undergoing hormonotherapy;

4. bad compliance with the instructions and follow-up;

5. allergic to nitinol and contrast medium;

6. estimated life expectancy is less than 24 months.